DK4308114T3 - C5ar1-hæmmere til behandling af overfølsomhedsreaktioner over for taxaner - Google Patents

C5ar1-hæmmere til behandling af overfølsomhedsreaktioner over for taxaner

Info

Publication number
DK4308114T3
DK4308114T3 DK22716203.9T DK22716203T DK4308114T3 DK 4308114 T3 DK4308114 T3 DK 4308114T3 DK 22716203 T DK22716203 T DK 22716203T DK 4308114 T3 DK4308114 T3 DK 4308114T3
Authority
DK
Denmark
Prior art keywords
c5ar1
taxanes
inhibitors
treatment
hypersensitivity reactions
Prior art date
Application number
DK22716203.9T
Other languages
Danish (da)
English (en)
Inventor
Marcello Allegretti
Andrea Aramini
Laura Brandolini
Maria Candida Cesta
Piergiorgio Amendola
Anna Sirico
Original Assignee
Dompe Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP21163292.2A external-priority patent/EP4059497A1/en
Application filed by Dompe Farm Spa filed Critical Dompe Farm Spa
Application granted granted Critical
Publication of DK4308114T3 publication Critical patent/DK4308114T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK22716203.9T 2021-03-17 2022-03-17 C5ar1-hæmmere til behandling af overfølsomhedsreaktioner over for taxaner DK4308114T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21163292.2A EP4059497A1 (en) 2021-03-17 2021-03-17 C5ar1 inhibitors for treating hypersensitivity reactions to taxanes
EP21217382 2021-12-23
PCT/EP2022/057007 WO2022195017A1 (en) 2021-03-17 2022-03-17 C5ar1 inhibitors for treating hypersensitivity reactions to taxanes

Publications (1)

Publication Number Publication Date
DK4308114T3 true DK4308114T3 (da) 2026-03-23

Family

ID=81307212

Family Applications (1)

Application Number Title Priority Date Filing Date
DK22716203.9T DK4308114T3 (da) 2021-03-17 2022-03-17 C5ar1-hæmmere til behandling af overfølsomhedsreaktioner over for taxaner

Country Status (15)

Country Link
US (1) US20240180888A1 (cg-RX-API-DMAC7.html)
EP (1) EP4308114B1 (cg-RX-API-DMAC7.html)
JP (1) JP2024512472A (cg-RX-API-DMAC7.html)
BR (1) BR112023018826A2 (cg-RX-API-DMAC7.html)
CA (1) CA3212816A1 (cg-RX-API-DMAC7.html)
DK (1) DK4308114T3 (cg-RX-API-DMAC7.html)
FI (1) FI4308114T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20260351T1 (cg-RX-API-DMAC7.html)
IL (1) IL305727A (cg-RX-API-DMAC7.html)
LT (1) LT4308114T (cg-RX-API-DMAC7.html)
PL (1) PL4308114T3 (cg-RX-API-DMAC7.html)
RS (1) RS67911B1 (cg-RX-API-DMAC7.html)
SI (1) SI4308114T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202600118T1 (cg-RX-API-DMAC7.html)
WO (1) WO2022195017A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202543631A (zh) * 2024-03-14 2025-11-16 美商凡況生化公司 嗒嗪酮c5ar1拮抗劑及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002500667A (ja) * 1997-05-27 2002-01-08 ベーカー ノートン ファーマシューティカルズ インコーポレイテッド 人間の患者に対して経口的にタキサン類を投薬するための方法及び組成物
DE69828615T2 (de) * 1997-10-31 2005-12-01 Walter Reed Army Institute Of Research Verwendung von inhibitoren der komplementaktivierung zur herstellung eines medikaments zur inhibierung von nebenwirkungen von pharmazeutischen zusammensetzungen, die amphiphile träger oder wirkstoffträger moleküle enthalten
RU2002113659A (ru) * 1999-10-27 2004-01-27 Бейкер Нортон Фармасьютикалз, Инк. (Us) Способ и композиции для перорального введения таксанов больным людям
JP5374157B2 (ja) * 2005-11-24 2013-12-25 ドムペ・ファ.ル.マ・ソチエタ・ペル・アツィオーニ (r)−アリールアルキルアミノ誘導体類と、それらを含有する薬剤組成物
EP3498269A1 (en) * 2017-12-12 2019-06-19 Dompé farmaceutici S.p.A. C5ar inhibitors for use in the treatment of chemotherapy-induced iatrogenic pain

Also Published As

Publication number Publication date
US20240180888A1 (en) 2024-06-06
PL4308114T3 (pl) 2026-05-04
EP4308114B1 (en) 2026-02-11
RS67911B1 (sr) 2026-04-30
EP4308114A1 (en) 2024-01-24
WO2022195017A1 (en) 2022-09-22
FI4308114T3 (fi) 2026-03-25
IL305727A (en) 2023-11-01
JP2024512472A (ja) 2024-03-19
LT4308114T (lt) 2026-03-25
CA3212816A1 (en) 2022-09-22
BR112023018826A2 (pt) 2024-03-12
HRP20260351T1 (hr) 2026-04-24
SI4308114T1 (sl) 2026-05-29
SMT202600118T1 (it) 2026-05-12

Similar Documents

Publication Publication Date Title
IL283042A (en) Compounds and compositions for treating conditions associated with nlrp activity
IL292754A (en) Method of synthesis
DK3773593T3 (da) Behandling af hidradenitis suppurativa under anvendelse af JAK-inhibitorer
DK3445767T3 (da) Makrocykliske mcl1-inhibitorer til behandling af cancer
DK3498278T3 (da) Forbindelser til behandling af sygdomme relateret til DUX4-ekspression
EA201792496A1 (ru) Способы лечения воспаления или нейропатической боли
IL261015B (en) Methylamine derivatives as lysysl oxidase inhibitors for the treatment of cancer
DK3377516T3 (da) Sammensætning til behandling af cancer
HUE039809T2 (hu) Vegyület karbamid-tartalmú mûtrágyák kezelésére
DK3728410T3 (da) Fremgangsmåde til behandling af lignocelluloseholdig biomasse
IL287904A (en) Combination treatment of arthritic disease
DK3261726T3 (da) Sammensætning til behandling af acne
DK3386991T3 (da) Polycykliske forbindelser som inhibitorer af bruton's tyrosinkinase
DK4101454T3 (da) Sammensætninger til behandling af hypertension
DK4447683T3 (da) Anvendelse af isoxazolincarboxamid til hæmning af spiring
SI3833665T1 (sl) Diazabiciklooktanoni kot zaviralci serinskih beta-laktamaz
DK3638293T3 (da) Sammensætninger til behandling af cancer
PL3552017T3 (pl) Związki użyteczne jako inhibitory RIPK1
IL281742A (en) Novel compounds as nadph oxidase inhibitors
IL282041A (en) Egfr inhibitors for treating keratodermas
IL289313A (en) Treatment of pain using allosteric modulator of trpv1
DK3403674T3 (da) Farmaceutiske sammensætninger til behandling af smerte
DK3880186T3 (da) Intralæsional administration af pd-1-hæmmere til behandling af hudcancer
IL291424A (en) Use of dkk-1 inhibitors for treating cancer
DK4125911T3 (da) Obicetrapib til behandling af demens